List of Tauvid drug patents
Tauvid is owned by Avid Radiopharms Inc.
Tauvid contains Flortaucipir F-18.
Tauvid has a total of 1 drug patent out of which 0 drug patents have expired.
Tauvid was authorised for market use on 28 May, 2020.
Tauvid is available in solution;intravenous dosage forms.
Drug patent challenges can be filed against Tauvid from May, 2024.
The generics of Tauvid are possible to be released after 19 May, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8932557 | AVID RADIOPHARMS INC | Imaging agents for detecting neurological dysfunction |
May, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 28, 2025 |
Drugs and Companies using FLORTAUCIPIR F-18 ingredient
NCE-1 date: May, 2024
Market Authorisation Date: 28 May, 2020
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic